20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Protective barrier properties of Rhinosectan ® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          To evaluate barrier protective properties of Rhinosectan ® spray, a medical device containing xyloglucan, on nasal epithelial cells (MucilAir).

          Methods

          MucilAir-Nasal, a three-dimensional organotypic (with different cell types) airway tissue model, was treated with the medical device Rhinosectan ® (30 µL) or with controls (Rhinocort—budesonide—or saline solution). The protective barrier effects of Rhinosectan ® were evaluated by: TEER (trans-epithelial electrical resistance) (preservation of tight junctions), Lucifer Yellow assay (preservation of paracellular flux) and confocal immunofluorescence microscopy (localization of tight junction proteins).

          Results

          Exposure of MucilAir with Rhinosectan ® protected cell tight junctions (increases in TEER of 13.1% vs −6.3% with saline solution after 1 h of exposure), and preserved the paracellular flux, even after exposure with pro-inflammatory compounds (TNF-α and LPS from Pseudomonas aeruginosa 10). Results of confocal immunofluorescence microscopy demonstrated that, after treatment with the pro-inflammatory mixture, Rhinosectan ® produced a slight relocation of zona occludens-1 in the cytosol compartment (while Rhinocort induced expression of zona-occludens-1), maintaining the localization of occludin (similarly to negative control).

          Conclusions

          Results of our study indicates that Rhinosectan ® creates a protective physical barrier on nasal epithelial cells in vitro, allowing the avoidance of allergens and triggering factors, thus confirming the utility of this medical device in the management of nasal respiratory diseases, as rhinitis or rhinosinusitis.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision.

          Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice. Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Innate immunity.

            Recent years have witnessed an explosion of interest in the innate immune system. Questions about how the innate immune system senses infection and empowers a protective immune response are being answered at the molecular level. These basic science discoveries are being translated into a more complete understanding of the central role innate immunity plays in the pathogenesis of many human infectious and inflammatory diseases. It is particularly exciting that we are already seeing a return on these scientific investments with the emergence of novel therapies to harness the power of the innate immune system. In this review we explore the defining characteristics of the innate immune system, and through more detailed examples, we highlight recent breakthroughs that have advanced our understanding of the role of innate immunity in human health and disease. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression.

              Tight junction (TJ) defects have recently been associated with asthma and chronic rhinosinusitis. The expression, function, and regulation of nasal epithelial TJs remain unknown in patients with allergic rhinitis (AR).
                Bookmark

                Author and article information

                Contributors
                barbara.deservi@vitroscreen.com
                francesco.ranzini@vitroscreen.com
                +34 93 402 44 96 , npique@ub.edu
                Journal
                Allergy Asthma Clin Immunol
                Allergy Asthma Clin Immunol
                Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
                BioMed Central (London )
                1710-1484
                1710-1492
                10 August 2017
                10 August 2017
                2017
                : 13
                : 37
                Affiliations
                [1 ]VitroScreen Srl, Via Mosè Bianchi 103, 20149 Milan, Italy
                [2 ]ISNI 0000 0004 1937 0247, GRID grid.5841.8, Department of Microbiology and Parasitology, Diagonal Sud, Facultat de Farmàcia, , Universitat de Barcelona (UB), ; Edifici A, Av Joan XXIII, 08028 Barcelona, Spain
                Author information
                http://orcid.org/0000-0002-7308-030X
                Article
                209
                10.1186/s13223-017-0209-6
                5553660
                28811823
                2ff8f176-a564-40a8-8774-8557863f47c7
                © The Author(s) 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 9 May 2017
                : 2 August 2017
                Funding
                Funded by: Novintethical Pharma SA
                Categories
                Research
                Custom metadata
                © The Author(s) 2017

                Immunology
                nasal obstruction,rhinitis,rhinosinusitis,orgatypic 3d airway tissue model (mucilair),rhinosectan®,xyloglucan,barrier properties,allergy,preventive measures

                Comments

                Comment on this article